3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
114
Neoplasms
28
Lung Neoplasms
24
Non-Squamous Non-Small Cell Lung Cancer
21
Pancreatic Neoplasms
13
Colorectal Neoplasms
6
Neoplasm Metastasis
5
Breast Neoplasms
4
Respiratory Tract Neoplasms
3
Respiratory Tract Diseases
3
Lymphoma
3
Thoracic Neoplasms
2
Solid Tumors
2
Recurrence
2
Neoplasms by Site
2
Lung Diseases
2
Familial ependymoma
2
Ependymoma
2
Carcinoma, Renal Cell
2
Carcinoma, Hepatocellular
2
Carcinoma
2
Bronchial Neoplasms
2
Advanced Solid Tumors
2
Vascular Diseases
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Smoking
1
Small Cell Lung Carcinoma
1
Interventions
Dexamethasone
17
Bortezomib
11
pomalidomide
10
carfilzomib
6
Lenalidomide
4
imetelstat
3
fludarabine
3
daratumumab
3
Standard of Care
3
Panobinostat
3
venetoclax
2
siltuximab
2
elotuzumab
2
Cyclophosphamide
2
Arsenic Trioxide
2
spartalizumab
1
shark cartilage extract
1
selinexor
1
saracatinib
1
ricolinostat
1
resiquimod
1
poly ICLC
1
plitidepsin
1
pembrolizumab
1
pazopanib
1
motexafin gadolinium
1
marizomib
1
liposomal doxorubicin
1
lestaurtinib
1
isatuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Neoplasms, Plasma Cell
×
Erlotinib Hydrochloride
×
Clear all
NCT00725634
2014-01-27
P05538
AVEO Pharmaceuticals, Inc.
Phase 1
Completed
41 enrolled